• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hepatocellular Carcinoma: Portuguese Data in Chronic Hepatitis B Patients on Antiviral Therapy and Treatment Results With Sorafenib.

作者信息

Simão Adélia

机构信息

Internal Medicine A, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.

出版信息

GE Port J Gastroenterol. 2016 Sep 3;23(5):231-232. doi: 10.1016/j.jpge.2016.08.001. eCollection 2016 Sep-Oct.

DOI:10.1016/j.jpge.2016.08.001
PMID:28868467
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5580183/
Abstract
摘要

相似文献

1
Hepatocellular Carcinoma: Portuguese Data in Chronic Hepatitis B Patients on Antiviral Therapy and Treatment Results With Sorafenib.肝细胞癌：慢性乙型肝炎患者接受抗病毒治疗的葡萄牙数据及索拉非尼的治疗结果
GE Port J Gastroenterol. 2016 Sep 3;23(5):231-232. doi: 10.1016/j.jpge.2016.08.001. eCollection 2016 Sep-Oct.
2
Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.索拉非尼治疗晚期乙型肝炎病毒相关肝细胞癌患者抗病毒治疗的成本效益分析
J Gastroenterol Hepatol. 2016 Dec;31(12):1978-1985. doi: 10.1111/jgh.13425.
3
Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.抗病毒治疗对索拉非尼治疗的乙型肝炎病毒相关肝细胞癌患者生存的改善作用
J Gastroenterol Hepatol. 2015 Jun;30(6):1032-9. doi: 10.1111/jgh.12910.
4
A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib.高基线乙肝病毒载量和抗病毒治疗影响索拉非尼治疗的晚期乙肝相关肝细胞癌患者的生存。
Liver Int. 2015 Sep;35(9):2147-54. doi: 10.1111/liv.12805. Epub 2015 Mar 7.
5
Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib.乙肝病毒载量可预测接受索拉非尼治疗的肝细胞癌患者的生存率。
J Gastroenterol Hepatol. 2015 Jun;30(6):1024-31. doi: 10.1111/jgh.12898.
6
Prospective analysis of tiopronin in prevention of sorafenib and antiviral therapy inducing liver toxicity in advanced hepatitis B virus-related hepatocellular carcinoma.硫普罗宁预防索拉非尼及抗病毒治疗所致晚期乙型肝炎病毒相关肝细胞癌肝毒性的前瞻性分析
Med Oncol. 2015 Oct;32(10):238. doi: 10.1007/s12032-015-0684-x. Epub 2015 Sep 2.
7
Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors.索拉非尼治疗肝外转移的肝细胞癌：治疗结果和预后因素。
J Hepatol. 2015 May;62(5):1112-21. doi: 10.1016/j.jhep.2014.12.009. Epub 2014 Dec 13.
8
Perioperative antiviral therapy for chronic hepatitis B-related hepatocellular carcinoma.围手术期抗病毒治疗慢性乙型肝炎相关肝细胞癌。
Hepatobiliary Pancreat Dis Int. 2013 Jun;12(3):251-5. doi: 10.1016/s1499-3872(13)60041-7.
9
To treat or not to treat - Successful hepatitis C virus eradication in a patient with advanced hepatocellular carcinoma and complete response to sorafenib.治疗还是不治疗——晚期肝细胞癌患者丙型肝炎病毒成功根除且对索拉非尼完全缓解
Z Gastroenterol. 2017 Jun;55(6):564-568. doi: 10.1055/s-0042-118232. Epub 2016 Nov 2.
10
Exceptional serological and radiological response to sorafenib in 2 patients with advanced hepatocellular carcinoma and chronic hepatitis C viral infection: case report and review of the literature.2例晚期肝细胞癌合并慢性丙型肝炎病毒感染患者对索拉非尼产生显著血清学和影像学反应：病例报告及文献综述
BMC Gastroenterol. 2017 Feb 14;17(1):30. doi: 10.1186/s12876-017-0585-x.

引用本文的文献

1
Anticancer Effects and Mechanisms of Action of Plumbagin: Review of Research Advances.白花丹素的抗癌作用及其作用机制：研究进展综述。
Biomed Res Int. 2020 Dec 1;2020:6940953. doi: 10.1155/2020/6940953. eCollection 2020.

本文引用的文献

1
Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma.诱导不良事件的耐受性可增加索拉非尼的药物暴露量，并优化晚期肝细胞癌患者的治疗结局。
Liver Int. 2016 Jul;36(7):1033-42. doi: 10.1111/liv.13052. Epub 2016 Jan 20.
2
Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma.皮肤毒性可预测晚期肝细胞癌患者对索拉非尼的疗效。
World J Hepatol. 2014 Sep 27;6(9):670-6. doi: 10.4254/wjh.v6.i9.670.
3
Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib.早期皮肤不良事件预示着索拉非尼治疗 HCC 患者的更好结局。
J Hepatol. 2014 Aug;61(2):318-24. doi: 10.1016/j.jhep.2014.03.030. Epub 2014 Apr 2.
4
Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection.预防慢性乙型和丙型病毒性肝炎相关肝细胞癌。
World J Gastroenterol. 2013 Dec 21;19(47):8887-94. doi: 10.3748/wjg.v19.i47.8887.
5
Epidemiology of hepatocellular carcinoma: consider the population.肝细胞癌的流行病学：从人群角度考虑。
J Clin Gastroenterol. 2013 Jul;47 Suppl(0):S2-6. doi: 10.1097/MCG.0b013e3182872f29.
6
Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy.索拉非尼治疗晚期肝细胞癌：高血压可能成为疗效的替代标志物。
Am J Clin Oncol. 2013 Aug;36(4):319-24. doi: 10.1097/COC.0b013e3182468039.
7
Diarrhea predicts a positive response to sorafenib in patients with advanced hepatocellular carcinoma.
Hepatology. 2012 Aug;56(2):789-90. doi: 10.1002/hep.25637. Epub 2012 Jul 6.
8
Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib.早期皮肤毒性作为索拉非尼治疗肝细胞癌患者肿瘤控制的预测因素。
Oncologist. 2010;15(1):85-92. doi: 10.1634/theoncologist.2009-0143. Epub 2010 Jan 5.
9
Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.1975年至2005年美国肝细胞癌的发病率、死亡率及生存趋势
J Clin Oncol. 2009 Mar 20;27(9):1485-91. doi: 10.1200/JCO.2008.20.7753. Epub 2009 Feb 17.
10
Rising costs and hospital admissions for hepatocellular carcinoma in Portugal (1993-2005).葡萄牙肝细胞癌的成本上升及住院情况（1993 - 2005年）
World J Gastroenterol. 2007 Mar 14;13(10):1522-7. doi: 10.3748/wjg.v13.i10.1522.